Loading
Latest filing published 11 Aug 2020 for Skye Bioscience, Inc..
No signal scores available.
Not enough history yet: 0 closed purchases, at least 2 are needed.
This profile gathers the share dealings of James L. Heppell across 2 companies, led by Sophiris Bio Inc. and Skye Bioscience, Inc. We count 3 filings; the first trade dates from 28 July 2016 and the latest from 7 August 2020.
Purchases make up the whole of the open-market record (1 purchase). The totals exclude 1 filing filed without an amount. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. 2020 to date brings 1 purchase and no sales.
Most recently, on 11 August 2020, the filings show an open-market purchase in Skye Bioscience, Inc. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations